查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529701

疫苗市场规模、份额、趋势分析报告：按类型、途径、适应疾病、年龄层、分销管道、地区、细分市场预测，2024-2030

Vaccine Market Size, Share & Trends Analysis Report By Type (Subunit, mRNA), By Route Of Administration (Oral), By Disease Indication (HPV, MMR), By Age Group (Adult), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

疫苗市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年全球疫苗市场规模将达到1,105.4亿美元。

预计202年至2030年该市场将以5.74%的复合年增长率扩张。免疫计划的增加以及呼吸道合胞病毒和披衣菌感染等疾病疫苗的开发推动了成长。在改善公共卫生问题疫苗的取得方面已经取得了重大进展。许多新疫苗已被开发出来并在全球范围内分发，从而挽救了无数生命并预防了多种疾病。

此外，疫苗市场上还有多项旨在改善疫苗可近性、开发新疫苗和确保疫苗安全的倡议。这些倡议涉及国际组织、政府、私人公司和慈善组织。透过合作和创新，这些倡议正在帮助应对全球健康挑战并改善公共卫生成果。例如，COVAX 是一项旨在确保公平获得新冠疫苗的全球倡议。该倡议由全球疫苗免疫联盟、疫苗联盟、世界卫生组织（WHO）和流行病防范创新联盟（CEPI）共同主导。

到 2021 年，将有 90 多家疫苗製造商向世界卫生组织 (WHO) 成员国供应疫苗，但供应仍然严重依赖拥有多种可部署可用技术和全球影响力的不到 10 家製造商。这种集中导致了区域供应不安全和市场健康问题，特别是在非洲和东地中海地区。在美国，预计新冠疫苗市场可能在 2023 年下半年实现私有化。这种私有化可能会提高新冠疫苗的价格，并向其他参与者开放市场。例如，Moderna 和辉瑞 BioNTech 都宣布，各自的 mRNA COVID 疫苗的价格可能会提高至每剂约 110-130 美元。

疫苗市场亮点

  • 从疫苗类型来看，mRNA领域在疫苗市场占据主导地位，2023年市占率为32.32%。然而，次单位疫苗领域预计在预测期内将以 8.1% 的复合年增长率增长最快。
  • 从给药途径来看，在预测期内，肠外给药预计将占据疫苗市场占有率的大部分份额。肠外给药有助于此细分市场的主导地位，因为与其他给药途径相比，它降低了污染风险。
  • 以疾病指示来看，病毒性疾病细分市场在 2023 年占据了疫苗市场的最大份额，这主要是由于 2021 年和 2022 年 COVID-19 疫苗的高分布。
  • 按年龄组别划分，小儿科预计在预测期内将增长最快。这是因为许多国家都有国家免疫规划，要求将某些疫苗接种作为常规儿童免疫接种的一部分。
  • 以销售管道来看，药局预计成长最快。这一增长的推动因素是患者的可及性和便利性的增加以及药房收益和利润率增加的潜力。
  • 预计北美地区在预测期内将以最快的复合年增长率成长。该地区由几家主要企业主导，包括辉瑞（Pfizer）、Moderna、赛诺菲巴斯德（Sanofi Pasteur）和默克（Merck）。由于建立了分销网络以及在疫苗研发方面的大量投资，这些公司在市场上拥有强大的影响力。

目录

第一章调查方法与范围

第二章 市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场趋势及展望
  • 市场动态
    • 疫苗接种的重要性在世界各地日益增加
    • 慢性病和感染疾病负担日益加重
    • 疫苗研发的技术进步
  • 市场限制因素分析
    • 缺乏医疗基础设施
    • 疫苗接种费用
  • 营商环境分析
    • SWOT 分析；按因素（政治/法律、经济/技术）
    • 波特五力分析
  • COVID-19 影响分析

第三章按类型分類的业务分析

  • 2023 年和 2030 年按类型分類的市场占有率
  • 细分仪表板
  • 按类型分類的疫苗市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 次单位疫苗
    • 次单位疫苗市场，2018-2030
    • 重组疫苗
    • 结合疫苗
    • 类毒素疫苗
  • 惰性
    • 灭活疫苗市场，2018-2030
  • 减毒活
    • 减毒活疫苗市场，2018-2030
  • mRNA疫苗
    • mRNA疫苗的疫苗市场，2018-2030年
  • 病毒载体疫苗
    • 病毒载体疫苗市场，2018-2030

第 4 章 依途径进行的业务分析

  • 2023 年及 2030 年给药途径市场占有率
  • 细分仪表板
  • 途径的疫苗市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 口服
    • 口服疫苗市场，2018-2030
  • 胃肠外的
    • 2018-2030年註射疫苗市场
  • 鼻腔
    • 经鼻吸入型疫苗市场，2018-2030

第五章 疾病适应症业务分析

  • 2023年及2030年疾病适应症市场占有率
  • 细分仪表板
  • 按疾病适应症分類的疫苗市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 病毒性疾病
    • 病毒性疾病疫苗市场，2018-2030
    • 肝炎
    • 流感
    • HPV
    • MMR
    • 轮状病毒
    • 带状疱疹
    • COVID-19
    • 其他的
  • 细菌疫苗
    • 细菌疫苗疫苗市场，2018-2030
    • 病菌感染
    • 肺炎链球菌感染
    • 二氧化硅
    • 其他的
  • 癌症疫苗
    • 2018-2030年癌症疫苗疫苗市场
  • 过敏疫苗
    • 过敏疫苗疫苗市场，2018-2030

第六章依年龄族群进行的业务分析

  • 2023年及2030年按年龄族群分類的市场占有率
  • 细分仪表板
  • 按年龄组别分類的疫苗市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 儿科的
    • 儿科疫苗市场，2018-2030
  • 成人
    • 成人疫苗市场，2018-2030

第七章 通路业务分析

  • 2023 年及 2030 年分销通路市场占有率
  • 细分仪表板
  • 按分销管道分類的疫苗市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 医院和药房
    • 医院和零售药房疫苗市场，2018-2030
  • 政府供应商
    • 2018-2030 年政府供应商疫苗市场
  • 其他的
    • 其他疫苗市场，2018-2030

第八章区域业务分析

  • 2023 年及 2030 年按地区分類的疫苗市场占有率份额
  • 北美洲
    • 2018-2030年北美疫苗市场
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030年欧洲疫苗市场
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太疫苗市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 拉丁美洲疫苗市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 2018-2030年中东和非洲疫苗市场
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 参与企业概况
  • 财务表现
  • 参与企业
    • 市场领导者
    • 2023 年疫苗市场占有率分析
    • 公司简介
    • 策略规划
      • Serum Institute of India Pvt. Ltd.
      • Seqirus
      • Sanofi
      • GSK Plc.
      • Merck & Co., Inc.
      • Pfizer Inc.
      • Moderna Inc.
      • Sinovac
      • BioNTech SE
      • AstraZeneca
    • 策略规划
Product Code: 978-1-68038-990-6

Vaccine Market Growth & Trends:

The global vaccine market size is expected to reach USD 110.54 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.74% from 202 to 2030. The growth is attributed to the rising immunization programmes, and the development of vaccines for diseases, such as RSV and Chlamydia amongst others. There has been significant progress in improving access to vaccines for diseases of public health concern. Many new vaccines have been developed and distributed globally, resulting in the saving of countless lives and the prevention of various illnesses.

Furthermore, there are several initiatives in the vaccine market aimed at improving access to vaccines, developing new vaccines, and ensuring vaccine safety. These initiatives involve international organizations, governments, private sector entities, and philanthropic organizations. Through collaboration and innovation, these initiatives are helping to address global health challenges and improve public health outcomes. For instance, COVAX is a global initiative aimed at ensuring equitable access to COVID vaccines. The initiative is co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations (CEPI).

Although there are over 90 vaccine manufacturers supplying vaccines to World Health Organization Member States in 2021, supply remains highly dependent on fewer than 10 manufacturers with diverse deployable technology and global reach. This concentration leads to regional supply insecurity and market health issues, particularly in the African and Eastern Mediterranean regions. It is anticipated that the COVID vaccine market could go private in the second half of 2023 in the U.S. This privatization may lead to an increase in prices of COVID vaccines and open up the market for other players as well. For instance, both Moderna and Pfizer BioNTech have announced that the prices of their respective mRNA COVID vaccines could increase to around USD 110 to USD 130 per shot.

Vaccine Market Report Highlights:

  • By type, the mRNA segment dominated the vaccine market with a share of 32.32% in 2023. However, the subunit vaccine segment is expected to grow at the fastest CAGR of 8.1% during the forecast period
  • By route of administration, the parenteral administration is anticipated to capture the majority of the vaccine market share throughout the forecast period. Parenteral administration reduces the risk of contamination compared to other routes of administration thus contributing to the segments' dominance
  • By disease indication, the viral diseases segment captured the largest share of the vaccine market in 2023, majorly attributed to the high distribution of COVID-19 vaccines during 2021 and 2022
  • By age, pediatrics is expected to witness the fastest growth during the forecast period, as many countries have established national immunization programs that require children to receive certain shots as part of routine childhood vaccinations
  • By distribution channel, pharmacies are anticipated to be the fastest-growing segment. This growth can be attributed to the increased accessibility and convenience for patients, and the potential for increased revenue and profitability for pharmacies
  • North America region is expected to grow at the fastest CAGR during the forecast period. The region is dominated by a few key players, including Pfizer, Moderna, Sanofi Pasteur, and Merck. These companies have a strong presence in the market, with established distribution networks and significant investment in vaccine research and development

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Route of Administration
    • 1.2.3. Disease Indication
    • 1.2.4. Age Group
    • 1.2.5. Distribution Channel
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Market Variables, Trends, & Scope

  • 2.1. Market Segmentation and Scope
  • 2.2. Market Lineage Outlook
    • 2.2.1. Parent Market Outlook
    • 2.2.2. Related/Ancillary Market Outlook
  • 2.3. Market Trends and Outlook
  • 2.4. Market Dynamics
    • 2.4.1. Rise in the importance of immunization across the globe
    • 2.4.2. Growing Burden of Chronic and Infectious Diseases
    • 2.4.3. Technology advancements in the vaccination development
  • 2.5. Market Restraint Analysis
    • 2.5.1. Lack of healthcare infrastructure
    • 2.5.2. Cost of immunization
  • 2.6. Business Environment Analysis
    • 2.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
    • 2.6.2. Porter's Five Forces Analysis
  • 2.7. COVID-19 Impact Analysis

Chapter 3. Type Business Analysis

  • 3.1. Type Market Share, 2023 & 2030
  • 3.2. Segment Dashboard
  • 3.3. Vaccines Market by Type Outlook
  • 3.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 3.5. Subunit Vaccines
    • 3.5.1. Vaccine Market for Subunit Vaccines, 2018 - 2030 (USD Billion)
    • 3.5.2. Recombinant vaccines
      • 3.5.2.1. Vaccine Market for Recombinant vaccines, 2018 - 2030 (USD Billion)
    • 3.5.3. Conjugate Vaccines
      • 3.5.3.1. Vaccine Market for Conjugate vaccines, 2018 - 2030 (USD Billion)
    • 3.5.4. Toxoid vaccines
      • 3.5.4.1. Vaccine Market for Toxoid vaccines, 2018 - 2030 (USD Billion)
  • 3.6. Inactivated
    • 3.6.1. Vaccine Market for Inactivated, 2018 - 2030 (USD Billion)
  • 3.7. Live Attenuated
    • 3.7.1. Vaccine Market for Live Attenuated, 2018 - 2030 (USD Billion)
  • 3.8. mRNA vaccines
    • 3.8.1. Vaccine Market for mRNA vaccines, 2018 - 2030 (USD Billion)
  • 3.9. Viral vector vaccines
    • 3.9.1. Vaccine Market for Viral vector vaccines, 2018 - 2030 (USD Billion)

Chapter 4. Route Of Administration Business Analysis

  • 4.1. Route of administration Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Vaccines Market by Route of administration Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Oral
    • 4.5.1. Vaccine Market for Oral, 2018 - 2030 (USD Billion)
  • 4.6. Parenteral
    • 4.6.1. Vaccine Market for Parenteral, 2018 - 2030 (USD Billion)
  • 4.7. Nasal
    • 4.7.1. Vaccine Market for Nasal, 2018 - 2030 (USD Billion)

Chapter 5. Disease Indication Business Analysis

  • 5.1. Disease Indication Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Vaccines Market by Disease Indication Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Viral Diseases
    • 5.5.1. Vaccine Market for Viral Diseases, 2018 - 2030 (USD Billion)
    • 5.5.2. Hepatitis
      • 5.5.2.1. Vaccine Market for Hepatitis, 2018 - 2030 (USD Billion)
    • 5.5.3. Influenza
      • 5.5.3.1. Vaccine Market for Influenza, 2018 - 2030 (USD Billion)
    • 5.5.4. HPV
      • 5.5.4.1. Vaccine Market for HPV, 2018 - 2030 (USD Billion)
    • 5.5.5. MMR
      • 5.5.5.1. Vaccine Market for MMR, 2018 - 2030 (USD Billion)
    • 5.5.6. Rotavirus
      • 5.5.6.1. Vaccine Market for Rotavirus, 2018 - 2030 (USD Billion)
    • 5.5.7. Herpes Zoster
      • 5.5.7.1. Vaccine Market for Herpes Zoster, 2018 - 2030 (USD Billion)
    • 5.5.8. COVID-19
      • 5.5.8.1. Vaccine Market for Covid-19, 2018 - 2030 (USD Billion)
    • 5.5.9. Others
      • 5.5.9.1. Vaccine Market for Others, 2018 - 2030 (USD Billion)
  • 5.6. Bacterial Vaccines
    • 5.6.1. Vaccine Market for Bacterial Vaccines, 2018 - 2030 (USD Billion)
    • 5.6.2. Meningococcal Diseases
      • 5.6.2.1. Vaccine Market for Meningococcal Diseases, 2018 - 2030 (USD Billion)
    • 5.6.3. Pneumococcal Diseases
      • 5.6.3.1. Vaccine Market for Pneumococcal Diseases, 2018 - 2030 (USD Billion)
    • 5.6.4. DPT
      • 5.6.4.1. Vaccine Market for DPT, 2018 - 2030 (USD Billion)
    • 5.6.5. Others
      • 5.6.5.1. Vaccine Market for Others, 2018 - 2030 (USD Billion)
  • 5.7. Cancer Vaccines
    • 5.7.1. Vaccine Market for Cancer Vaccines, 2018 - 2030 (USD Billion)
  • 5.8. Allergy Vaccines
    • 5.8.1. Vaccine Market for Allergy Vaccines, 2018 - 2030 (USD Billion)

Chapter 6. Age Group Business Analysis

  • 6.1. Age Group Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Vaccines Market by Age Group Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Pediatric
    • 6.5.1. Vaccine Market for Pediatric, 2018 - 2030 (USD Billion)
  • 6.6. Adult
    • 6.6.1. Vaccine Market for Adult, 2018 - 2030 (USD Billion)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Vaccines Market by Distribution Channel Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Hospital & Retail Pharmacies
    • 7.5.1. Vaccine Market for Hospital & Retail Pharmacies, 2018 - 2030 (USD Billion)
  • 7.6. Government Suppliers
    • 7.6.1. Vaccine Market for Government Suppliers 2018 - 2030 (USD Billion)
  • 7.7. Others
    • 7.7.1. Vaccine Market for Others, 2018 - 2030 (USD Billion)

Chapter 8. Regional Business Analysis

  • 8.1. Vaccine Market Share By Region, 2023 & 2030
  • 8.2. North America
    • 8.2.1. North America Vaccines Market 2018 - 2030 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Vaccine Market 2018 - 2030 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Vaccine Market 2018 - 2030 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Vaccines Market 2018 - 2030 (USD Billion)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Vaccine Market 2018 - 2030 (USD Billion)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Vaccine Market 2018 - 2030 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Vaccine Market 2018 - 2030 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Vaccine Market 2018 - 2030 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Vaccine Market 2018 - 2030 (USD Billion)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Vaccine Market 2018 - 2030 (USD Billion)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Vaccine Market 2018 - 2030 (USD Billion)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Vaccine Market 2018 - 2030 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Vaccine Market, 2018 - 2030 (USD Billion)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Vaccine Market 2018 - 2030 (USD Billion)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Vaccine Market 2018 - 2030 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Vaccine Market 2018 - 2030 (USD Billion)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Vaccine Market 2018 - 2030 (USD Billion)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Vaccine Market 2018 - 2030 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Vaccine Market 2018 - 2030 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Vaccine Market, 2018 - 2030 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Vaccine Market 2018 - 2030 (USD Billion)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Mexico Vaccine Market 2018 - 2030 (USD Billion)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Argentina Vaccine Market 2018 - 2030 (USD Billion)
  • 8.6. MEA
    • 8.6.1. MEA Vaccine Market, 2018 - 2030 (USD Billion)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Vaccine Market 2018 - 2030 (USD Billion)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Vaccine Market 2018 - 2030 (USD Billion)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Vaccine Market 2018 - 2030 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Vaccine Market 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Vaccine Market Share Analysis, 2023
    • 9.3.3. Company Profiles
      • 9.3.3.1. Serum Institute of India Pvt. Ltd.
      • 9.3.3.1.1. Company Overview
      • 9.3.3.1.2. Financial Performance
      • 9.3.3.1.3. Product Benchmarking
      • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Seqirus
      • 9.3.3.2.1. Company Overview
      • 9.3.3.2.2. Financial Performance
      • 9.3.3.2.3. Product Benchmarking
      • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. Sanofi
      • 9.3.3.3.1. Company Overview
      • 9.3.3.3.2. Financial Performance
      • 9.3.3.3.3. Product Benchmarking
      • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. GSK Plc.
      • 9.3.3.4.1. Company Overview
      • 9.3.3.4.2. Financial Performance
      • 9.3.3.4.3. Product Benchmarking
      • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. Merck & Co., Inc.
      • 9.3.3.5.1. Company Overview
      • 9.3.3.5.2. Financial Performance
      • 9.3.3.5.3. Product Benchmarking
      • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Pfizer Inc.
      • 9.3.3.6.1. Company Overview
      • 9.3.3.6.2. Financial Performance
      • 9.3.3.6.3. Product Benchmarking
      • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. Moderna Inc.
      • 9.3.3.7.1. Company Overview
      • 9.3.3.7.2. Financial Performance
      • 9.3.3.7.3. Product Benchmarking
      • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Sinovac
      • 9.3.3.8.1. Company Overview
      • 9.3.3.8.2. Financial Performance
      • 9.3.3.8.3. Product Benchmarking
      • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. BioNTech SE
      • 9.3.3.9.1. Company Overview
      • 9.3.3.9.2. Financial Performance
      • 9.3.3.9.3. Product Benchmarking
      • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. AstraZeneca
      • 9.3.3.10.1. Company Overview
      • 9.3.3.10.2. Financial Performance
      • 9.3.3.10.3. Product Benchmarking
      • 9.3.3.10.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Product/Service Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Vaccine Market, by Region, 2018 - 2030 (USD Billion)
  • Table 4 Global Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 5 Global Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 6 Global Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 7 Global Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 8 Global Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 9 North America Vaccine Market, by Country, 2018 - 2030 (USD Billion)
  • Table 10 North America Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 11 North America Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 12 North America Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 13 North America Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 14 North America Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 15 U.S. Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 16 U.S. Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 17 U.S. Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 18 U.S. Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 19 U.S. Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 20 Canada Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 21 Canada Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 22 Canada Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 23 Canada Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 24 Canada Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 25 Europe Vaccine Market, by Country, 2018 - 2030 (USD Billion)
  • Table 26 Europe Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 27 Europe Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 28 Europe Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 29 Europe Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 30 Europe Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 31 Germany Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 32 Germany Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 33 Germany Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 34 Germany Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 35 Germany Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 36 UK Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 37 UK Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 38 UK Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 39 UK Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 40 UK Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 41 France Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 42 France Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 43 France Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 44 France Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 45 France Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 46 Italy Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 47 Italy Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 48 Italy Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 49 Italy Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 50 Italy Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 51 Spain Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 52 Spain Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 53 Spain Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 54 Spain Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 55 Spain Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 56 Denmark Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 57 Denmark Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 58 Denmark Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 59 Denmark Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 60 Denmark Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 61 Sweden Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 62 Sweden Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 63 Sweden Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 64 Sweden Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 65 Sweden Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 66 Norway Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 67 Norway Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 68 Norway Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 69 Norway Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 70 Norway Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 71 Asia Pacific Vaccine Market, by Country, 2018 - 2030 (USD Billion)
  • Table 72 Asia Pacific Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 73 Asia Pacific Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 74 Asia Pacific Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 75 Asia Pacific Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 76 Asia Pacific Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 77 China Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 78 China Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 79 China Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 80 China Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 81 China Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 82 Japan Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 83 Japan Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 84 Japan Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 85 Japan Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 86 Japan Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 87 India Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 88 India Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 89 India Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 90 India Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 91 India Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 92 South Korea Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 93 South Korea Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 94 South Korea Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 95 South Korea Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 96 South Korea Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 97 Australia Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 98 Australia Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 99 Australia Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 100 Australia Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 101 Australia Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 102 Thailand Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 103 Thailand Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 104 Thailand Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 105 Thailand Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 106 Thailand Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 107 Latin America Vaccine Market, by Country, 2018 - 2030 (USD Billion)
  • Table 108 Latin America Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 109 Latin America Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 110 Latin America Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 111 Latin America Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 112 Latin America Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 113 Brazil Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 114 Brazil Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 115 Brazil Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 116 Brazil Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 117 Brazil Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 118 Mexico Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 119 Mexico Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 120 Mexico Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 121 Mexico Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 122 Mexico Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 123 Argentina Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 124 Argentina Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 125 Argentina Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 126 Argentina Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 127 Argentina Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 128 Middle East & Africa Vaccine Market, by Country, 2018 - 2030 (USD Billion)
  • Table 129 Middle East & Africa Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 130 Middle East & Africa Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 131 Middle East & Africa Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 132 Middle East & Africa Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 133 Middle East & Africa Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 134 South Africa Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 135 South Africa Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 136 South Africa Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 137 South Africa Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 138 South Africa Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 139 Saudi Arabia Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 140 Saudi Arabia Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 141 Saudi Arabia Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 142 Saudi Arabia Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 143 Saudi Arabia Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 144 UAE Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 145 UAE Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 146 UAE Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 147 UAE Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 148 UAE Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 149 Kuwait Vaccine Market, by Type, 2018 - 2030 (USD Billion)
  • Table 150 Kuwait Vaccine Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 151 Kuwait Vaccine Market, by Disease Indication, 2018 - 2030 (USD Billion)
  • Table 152 Kuwait Vaccine Market, by Age Group, 2018 - 2030 (USD Billion)
  • Table 153 Kuwait Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 154 Financial performance
  • Table 155 Key companies undergoing expansions
  • Table 156 Key companies undergoing acquisitions
  • Table 157 Key companies undergoing collaborations
  • Table 158 Key companies launching new products/services
  • Table 159 Key companies undergoing partnerships
  • Table 160 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Vaccine Market Segmentation
  • Fig. 7 Market Snapshot, 2023
  • Fig. 8 Market Trends & Outlook
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2023
  • Fig. 15 Global Vaccine Market: By Type, Movement Analysis
  • Fig. 16 Global Vaccine Market, for Subunit Vaccines, 2018 - 2030 (USD Billion)
  • Fig. 17 Global Vaccine Market, for Recombinant vaccines, 2018 - 2030 (USD Billion)
  • Fig. 18 Global Vaccine Market, for Conjugate Vaccines, 2018 - 2030 (USD Billion)
  • Fig. 19 Global Vaccine Market, for Toxoid vaccines, 2018 - 2030 (USD Billion)
  • Fig. 20 Global Vaccine Market, for Inactivated, 2018 - 2030 (USD Billion)
  • Fig. 21 Global Vaccine Market, for Live Attenuated2018 - 2030 (USD Billion)
  • Fig. 22 Global Vaccine Market, for mRNA vaccines, 2018 - 2030 (USD Billion)
  • Fig. 23 Global Vaccine Market, for Viral vector vaccines, 2018 - 2030 (USD Billion)
  • Fig. 24 Global Vaccine Market: By Route of Administration, Movement Analysis
  • Fig. 25 Global Vaccine Market, for Oral, 2018 - 2030 (USD Billion)
  • Fig. 26 Global Vaccine Market, for Parenteral, 2018 - 2030 (USD Billion)
  • Fig. 27 Global Vaccine Market, for Nasal2018 - 2030 (USD Billion)
  • Fig. 28 Global Vaccine Market: Disease Indication, Movement Analysis
  • Fig. 29 Global Vaccine Market, for Viral Diseases, 2018 - 2030 (USD Billion)
  • Fig. 30 Global Vaccine Market, for Hepatitis, 2018 - 2030 (USD Billion)
  • Fig. 31 Global Vaccine Market, for Influenza2018 - 2030 (USD Billion)
  • Fig. 32 Global Vaccine Market, for HPV, 2018 - 2030 (USD Billion)
  • Fig. 33 Global Vaccine Market, for MMR, 2018 - 2030 (USD Billion)
  • Fig. 34 Global Vaccine Market, for Rotavirus, 2018 - 2030 (USD Billion)
  • Fig. 35 Global Vaccine Market, for Herpes Zoster, 2018 - 2030 (USD Billion)
  • Fig. 36 Global Vaccine Market, for COVID-19, 2018 - 2030 (USD Billion)
  • Fig. 37 Global Vaccine Market, for Bacterial Vaccines, 2018 - 2030 (USD Billion)
  • Fig. 38 Global Vaccine Market, for Meningococcal Diseases, 2018 - 2030 (USD Billion)
  • Fig. 39 Global Vaccine Market, for Pneumococcal diseases, 2018 - 2030 (USD Billion)
  • Fig. 40 Global Vaccine Market, for DPT, 2018 - 2030 (USD Billion)
  • Fig. 41 Global Vaccine Market, for Others, 2018 - 2030 (USD Billion)
  • Fig. 42 Global Vaccine Market, for Cancer Vaccines, 2018 - 2030 (USD Billion)
  • Fig. 43 Global Vaccine Market, for Allergy Vaccines, 2018 - 2030 (USD Billion)
  • Fig. 44 Global Vaccine Market: Age Group, Movement Analysis
  • Fig. 45 Global Vaccine Market, for Pediatric,2018 - 2030 (USD Billion)
  • Fig. 46 Global Vaccine Market, for Adult ,2018 - 2030 (USD Billion)
  • Fig. 47 Global Vaccine Market: Distribution Channel, Movement Analysis
  • Fig. 48 Global Vaccine Market, for Hospital & Retail Pharmacies,2018 - 2030 (USD Billion)
  • Fig. 49 Global Vaccine Market, for Government Suppliers,2018 - 2030 (USD Billion)
  • Fig. 50 Global Vaccine Market, for Others2018 - 2030 (USD Billion)
  • Fig. 51 Regional Marketplace: Key Takeaways Vaccine Market,
  • Fig. 52 Regional Outlook, 2023 & 2030 Vaccine Market,
  • Fig. 53 Global Vaccine Market: Region Movement Analysis
  • Fig. 54 North America Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 55 U.S. Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 56 Canada Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 57 Europe Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 58 Germany Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 59 UK Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 60 France Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 61 Italy Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 62 Spain Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 63 Denmark Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 64 Sweden Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 65 Norway Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 66 Asia Pacific Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 67 Japan Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 68 China Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 69 India Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 70 Australia Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 71 South Korea Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 72 Thailand Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 73 Latin America Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 74 Brazil Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 75 Mexico Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 76 Argentina Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 77 Middle East and Africa Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 78 South Africa Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 79 Saudi Arabia Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 80 UAE Vaccine Market, 2018 - 2030 (USD Billion)
  • Fig. 81 Kuwait Vaccine Market, 2018 - 2030 (USD Billion)